AZD 6280Alternative Names: AZD6280
Latest Information Update: 12 Nov 2016
At a glance
- Originator AstraZeneca
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 29 Jul 2010 Discontinued - Phase-I for Anxiety disorders in United Kingdom (unspecified route)
- 07 Dec 2007 Phase-I clinical trials in Anxiety disorders in United Kingdom (unspecified route)